First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the <scp>ONO</scp>‐4538‐52/<scp>TASUKI</scp>‐52 randomized controlled trial
Hye Ryun Kim(Yonsei University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Jong Seok Lee(Brigham and Women's Hospital), Chong‐Jen Yu(National Taiwan University Hospital), Cheng‐Ta Yang(Shanghai Medical College of Fudan University), Nobuyuki Yamamoto(Wakayama Medical University), Jin‐Hyoung Kang(The Catholic University of Korea Seoul St. Mary's Hospital), Makoto Nishio(Japanese Foundation For Cancer Research), Shunichi Sugawara(Sendai Kousei Hospital), Hiroaki Akamatsu(Army Medical University), Toyoaki Hida(Saitama International Medical Center), Tatsuya Yoshida(Juntendo University), Yuichiro Ohe(National Cancer Center), Hiroshi Tanaka(Tokyo Medical and Dental University), Tomohide Tamura(St. Luke's International Hospital), Naoki Inui(Hamamatsu University School of Medicine), Shigeru Takahashi(Ono Pharmaceutical (Japan)), Ki Hyeong Lee(Chungbuk National University Hospital)
Cited by 26
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k